therapy and has the advantage of immediate availability and greater safety 3 . The Aim of this study was whether early immunotherapy (1 st week) reduces hospital (ICU) stay, morbidity and mortality.
Methods:
We have conducted a retrospective study from the patients admitted in the ICU of BSMMU and Millennium Heart and General hospital with the diagnosis of Guillain Barré syndrome. We have identified 43 patients from January 2007 to December 2008. We reviewed the medical records, admission registrar and individual patient files. We have used a structured questionnaire to get the demographic, clinical, laboratory diagnostic, management and therapeutic information.
We used MS access for data entry. We have analyzed data in using the data analysis software SPSS. We have determined P-value as 0.05 as statistically significant.
Results and interpretation:
Among 43 Guillain Barré syndrome patients, 25 percent patients were of age ranges between 10 years to 19 years. Seventy percent was male patients. Immunoglobulin had been administered in 15 patients. All the 28 patients had been developed respiratory failure were undergone mechanical ventilation. However, fifteen patients failed to wean from mechanical ventilation and extubation, therefore tracheostomy was performed in those patients. superior effect than treatment regime given alone 4 . Similarly a combined evidence from trials show no benefit from corticosteroid therapy and the results of a trials of the methylprednesolne is still awaiting 8 .
Fig.-2: Therapies and interventions
So it is evident that I/V IgG therapy alone in early phase of GBS is a better option for treatment.
Although the results of our study were not statistically significant (may be due to small sample size), but it is clinically proved that immunotherapy in early phase of GBS reduces mortality, morbidity, duration of hospital (ICU) stay in terms of percentage and mean. Immunotherapy is effective in GBS patients in Bangladesh as shown in other studies in different countries [3] [4] [5] [6] [7] .
